Apellis Pharmaceuticals, Inc. - APLS STOCK NEWS

Apellis Pharmaceuticals (Nasdaq: APLS) announced the approval of equity awards for 14 new employees, effective February 1, 2021, as part of their 2021 Inducement Stock Incentive Plan. This includes options to purchase 56,500 shares and 13,275 restricted stock units (RSUs) at an exercise price of $44.20, reflecting the common stock's closing price on the grant date. The options will vest over four years, while the RSUs will vest similar to the options. This move aims to attract talent critical to the company’s growth in targeted C3 therapies.

On January 26, 2021, Apellis Pharmaceuticals (Nasdaq:APLS) announced the successful completion of privately negotiated exchange transactions involving its 3.500% Convertible Senior Notes due 2026. Holders exchanged approximately $126.1 million of the Notes for 3,906,869 shares of common stock.

The shares issued are not registered under the Securities Act of 1933 and cannot be sold in the U.S. without proper registration or an exemption. Apellis remains focused on developing therapies for diseases linked to the complement cascade.

On January 21, 2021, Apellis Pharmaceuticals (NASDAQ: APLS) announced a virtual investor event titled Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy, scheduled for January 28, 2021. This event will highlight the unmet needs in Geographic Atrophy (GA) and discuss the intravitreal pegcetacoplan program, which is expected to yield Phase 3 GA results in Q3 2021. Renowned retinal specialists will participate, and the live webcast will be available on their website. A replay will be accessible for 90 days post-event.

Apellis Pharmaceuticals (Nasdaq:APLS) announced exchange agreements with holders of its 3.500% Convertible Senior Notes due 2026, totaling approximately $107.5 million. The holders will exchange these Notes for 2,232,808 shares of common stock, equating to 20.7792 shares per $1,000 principal amount of Notes. An additional share amount will be based on a formula involving the stock's average trading price. The transactions are expected to close on January 25, 2021, subject to customary conditions. The shares issued will not be registered under the Securities Act of 1933.

Apellis Pharmaceuticals (Nasdaq: APLS) has announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 10:50 a.m. ET. The presentation will be delivered by co-founder and CEO Cedric Francois, M.D., Ph.D., and can be accessed live via webcast on the company's website. A replay will be available for 90 days post-event. Apellis focuses on developing targeted therapies that address debilitating diseases linked to complement cascade activation, including hematology and ophthalmology.

Apellis Pharmaceuticals and Sobi announced positive results from the Phase 3 PEGASUS study on pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH), showing a mean hemoglobin increase of 2.7 g/dL at Week 48. 73% of pegcetacoplan-treated patients were transfusion-free. The treatment's safety profile was consistent with previous results, with no new safety signals. pegcetacoplan is under review by the FDA and EMA, with a target action date of May 14, 2021 for FDA. This study highlights pegcetacoplan's potential to improve the lives of patients suffering from PNH.

Apellis Pharmaceuticals (Nasdaq: APLS) presented data from the Phase 3 PEGASUS study at the ASH Annual Meeting, highlighting significant improvements in treatment responses and quality of life for pegcetacoplan compared to eculizumab in treating paroxysmal nocturnal hemoglobinuria (PNH). In the analysis, 70.7% of pegcetacoplan-treated patients achieved a good, major, or complete hematologic response, versus just 5.1% for eculizumab. Furthermore, pegcetacoplan showed substantial quality-of-life improvements, achieving near-normal levels in several measures while eculizumab-treated patients did not. Marketing applications are pending with the FDA and EMA.

Apellis Pharmaceuticals (Nasdaq: APLS) announced the grant of equity awards to two new employees as an inducement for employment, effective December 1, 2020. The awards include options for 13,400 shares and 6,700 restricted stock units (RSUs), approved on October 27 and November 16, 2020. The options have an exercise price of $46.82, matching the stock's closing price on the grant date. Vesting schedules for the options and RSUs are based on continued employment, with full vesting occurring over four years for options and annually for RSUs.

Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in the 2020 Evercore ISI HealthCONx Conference on December 3, 2020 at 1:25 p.m. ET. The event will feature a fireside chat with Cedric Francois, M.D., Ph.D., co-founder and CEO. Interested parties can access the live webcast via the company's Investors and Media section. A replay will be available for 90 days afterwards. Apellis specializes in targeted C3 therapies for debilitating diseases such as those in hematology, ophthalmology, nephrology, and neurology.